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OBJECTIVES: Deregulation of prostaglandin E2 (PGE2) levels reported in colorectal carcinogenesis contributes to key steps of
cancer development. Our aim was to evaluate the influence of the genetic variability in COX-2/HPGD/SLCO2A1/ABCC4 PGE2
pathway genes on the development and recurrence of colorectal adenomas.
METHODS: A case-control study was conducted gathering 480 unscreened individuals and 195 patients with personal history of
adenomas. A total of 43 tagSNPs were characterized using the Sequenom platform or real-time PCR.
RESULTS: Ten tagSNPs were identified as susceptibility biomarkers for the development of adenomas. The top three most
meaningful tagSNPs include the rs689466 in COX-2 (odds ratio (OR)= 3.23; 95% confidence interval (CI): 1.52–6.86), rs6439448 in
SLCO2A1 (OR= 0.38; 95% CI: 0.22–0.65) and rs1751051 in ABCC4 genes (OR= 2.75; 95% CI: 1.58–4.80). The best four-locus gene–
gene interaction model included the rs1346271, rs1863642 and rs12500316 single nucleotide polymorphisms in HPGD and
rs1678405 in ABCC4 genes and was associated with a 13-fold increased susceptibility (95% CI: 3.84–46.3, Po0.0001, cross-
validation (CV) accuracy: 0.78 and CV consistency: 8/10). Interesting, in low-risk patients the ABCC4 rs9524821AA genotype was
associated not only with a higher hazard ratio (HR= 2.93; 95% CI: 1.07–8.03), but half of these patients had adenoma recurrence at
60 months, considerably higher than the 21% noticed in low-risk patients.
CONCLUSIONS: Genetic polymorphisms in COX-2/PGE2 pathway appear to contribute to the development of colorectal adenomas
and influence the interval time to adenomas recurrence. The definition of risk models through the inclusion of genetic biomarkers
might improve the adherence and optimization of current screening and surveillance guidelines for colorectal cancer prevention.
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INTRODUCTION
Colorectal adenomas are well-characterized colorectal cancer
(CRC) precursors.1 Although most adenomas are asympto-
matic and do not progress into cancer, the majority of CRC will
develop through the adenoma-cancer sequence on an
average of 10–15 years.2 Over one-third of people will develop
at least one adenoma in their lifetime.3
CRC screening has been shown to reduce the incidence
and CRC mortality through the endoscopic detection and
removal of adenomas.4,5 Still, these patients are at increased
risk for developing metachronous adenomas or even cancer,
with a recurrence rate of 40–50%.6,7
Deregulation of COX-2 expression, observed in half of
adenomatous polyps, leads to an increased biosynthesis of
prostaglandin E2 (PGE2).
8 The pleiotropic effects of higher
levels of PGE2 contribute to key steps of cancer development
including stimulation of cell proliferation, angiogenesis, inva-
siveness and migration, inhibition of apoptosis and
immunosurveillance.9 The degradation of PG is mediated by
the NAD+-dependent 15-hydroxyprostaglandin dehydrogen-
ase (15-PGDH), encoded by the hydroxyprostaglandin dehy-
drogenase (HPGD) gene, which directly counteracts the
COX-2 oncogenic PGE2 pathway.
10 Furthermore, low levels
of rectal 15-PGDH were associated with increased adenoma
recurrence.11 The multidrug resistance-associated protein 4
(MRP4) and the prostaglandin transporter (PGT), encoded by
the ATP-binding cassete sub-family C member 4 (ABCC4)
gene and solute carrier organic anion transporter family,
member 2A1 (SLCO2A1) genes, respectively, are the specific
prostaglandin membrane transporters that regulate PGE2
levels in the extracellular microenvironment.12,13 PGT and
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MRP4 messenger RNA levels were reported to be inversely
regulated in human CRC, with PGT expression being
repressed and MRP4 up-regulated in CRC tissues and cell
lines leading to higher levels of PGE2 extracellularly thus
exacerbating the effects of COX-2/PGE2 pathway.
14
Considering that the aforementioned genes are not only
highly polymorphic but their expression span several folds,
one could hypothesize that an unbalance in PGE2 levels
reflecting potential functional polymorphisms might influence
colorectal carcinogenesis.
Our group has previously reported the involvement of several
polymorphisms in COX-2/HPGD/SLCO2A1/ABCC4 genes on
CRC development.15–17 Therefore, with this study we aimed to
investigate whether tagSNPs in these four genes were also
associated with earlier stages of colorectal tumor development.
To the best of our knowledge this study is the first to evaluate the
influence of polymorphisms in HPGD, SLCO2A1 and ABCC4
genes in the occurrence of colorectal metachronous lesions.
METHODS
Type of study and participants. A hospital-based case-
control study followed by a retrospective cohort was designed
involving a group of unscreened individuals and patients
diagnosed with colorectal adenomas recruited at the Portu-
guese Oncology Institute of Porto (IPO-Porto) or Centro
Hospitalar do Porto (CHP).
The Ethic committees at both institutes approved this project
and a written informed consent was given before enrollment.
Group of controls. The method of sampling is displayed in
Figure 1. Unscreened individuals between 50 and 75 years of
age, with no clinical evidence of CRC or other oncologic
malignancy were randomly recruited from the blood donor’s
service at IPO-Porto between July 2005 and February 2008.
Group of patients. Patients diagnosed with one or more
adenomas between 1996 and 2008 were enrolled in this
study after reviewing a colonoscopy database from the
Gastroenterology departments at IPO-Porto and CHP. The
inclusion criteria were as follows: (1) age between 50 and 75
years; (2) without history of inflammatory bowel disease or
family history of colorectal tumors; (3) without previous
diagnose of CRC; (4) with a total colonoscopy with good to
excellent preparation at diagnosis; (5) a normal total
colonoscopy with good to excellent preparation at least 1
year after the diagnosis, to exclude missed lesions at
diagnosis, followed by (6) at least one total colonoscopy with
good to excellent preparation with or without adenomas
detection, to estimate the recurrence status.
Nearly three thousand individuals had history of adenomas,
although onlyo10% complied with the inclusion criteria. Two
hundred and fifty-six patients were included in this study. From
these we were only able to obtain DNA samples from 195
patients. No differenceswere observed between demographic
variables, lifestyle habits and tumor characteristics between
these patients and the overall population of patients.
Collection and processing of biological samples. The
DNA was extracted from formalin-fixed paraffin-embedded
blocks of excised adenomas using the GRS Genomic DNA
Kit—Tissue, following the manufacturer’s protocol (GRiSP,
Porto, Portugal). The use of formalin-fixed paraffin-embedded
samples for single nucleotide polymorphism (SNP) genotyping
was previously validated by comparing the genotypes from 20
DNAs isolated from fresh peripheral blood and paired formalin-
fixed paraffin-embedded samples from CRC patients.15
Selection of polymorphisms. The strategy for polymorph-
isms selection and quality control has been described
elsewhere.15 In brief, 55 tagSNPs were included after being
retrieved from a set of common SNPs in the Caucasian
population of HapMap project (CEU): (1) with minor allele
frequency equal or superior to 0.15; (2) within the coding
region of the genes plus 2 Kb upstream and downstream; (3)
with a r2 superior to 0.8 and (4) that successfully converted to
the Sequenom platform.
Statistical analysis. The Hardy–Weinberg equilibrium was
tested by the Pearson’s goodness-of-fit test to compare the
observed vs. the expected distribution of genotypes among
the control population.
Data analysis was performed using the computer software
IBM Statistical Package for Social Sciences-SPSS (IBM Corp.,
Armonk, NY, USA) for Macintosh (version 19.0). Chi-square
analysis was used to compare categorical variables, using a
5% level of significance. Non-parametric Mann–Whitney test
was used to compare mean values between study groups.
Odds ratio (OR) and its 95% confidence interval (CI) were
calculated as a measure of the association between the
genetic variants and the risk for the development of colorectal
adenomas. The covariates age, sex, and smoking habits were
included in the logistic regression analysis. A bootstrap
resampling was used to assess the stability of risk estimates
(1,000 replications). The false-positive report probability
(FPRP) was used to confirm the noteworthiness of significant
findings on the overall risk for colorectal adenoma develop-
ment, according to the study by Wacholder et al.18 This
methodology helps answer the questions: “of all tested null
hypothesis that were rejected, what is the percentage of false
rejection?”. Three factors determine the magnitude of FPRP:
the prior probability of the hypothesis, i.e., the assumed
probability of a true association between a genetic variant and
a disease; α level or P value and; statistical power to detect the
OR of the alternative hypothesis at a given α level or P value.18
The FPRP threshold was set at 0.5, recommended for
underpowered initial studies18 and a moderate-to-high prior
probability range was assigned to detect an OR of 1.5 (0.01–
0.10). This interval was assumed in view of the available
epidemiological and functional data supporting the relevance of
the genes here addressed in colorectal carcinogenesis.8,11,14,15
Haplotype analysis was performed at a gene level using the
SNPStats software (www.http://bioinfo.iconcologia.net/SNPstats).
The haplotype frequencieswere estimated using the implementa-
tion of the EM algorithm coded into the haplo.stats package. The
most frequent haplotype was automatically selected as the
reference category. After excluding the genetic variations most
likely to represent false-positive findings, all polymorphisms with
significant associations were included within each gene.
The open-source multifactor dimensionality reduction soft-
ware (version 3.0.2; www.epistasis.org) was used to assess
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potential gene–gene interactions between SNPs with statis-
tical significant impact on colorectal adenoma genetic
susceptibility. The fitness of an multifactor dimensionality
reduction model was estimated by determining the testing
accuracy and its cross-validation consistency. Using a 10-fold
cross-validation method the data was divided into 10 sets, in
which nine subsets were training sets and one subset was a
test set. Hence, the cross-validation consistency is a measure
of the number of times of 10 divisions of the data set the best
model was extracted. Statistical significance was evaluated
using a 1,000-fold permutation test to the compare observed
testing accuracies with those expected under the null
hypothesis of null association. Permutation testing corrects
for multiple testing by repeating the entire analysis on 1,000
data sets consistent with the null hypothesis.
Kaplan–Meier curves were used to evaluate the correlation
between the genetic variants and time to recurrence; log-rank
statistical test was used for curves comparison.
RESULTS
Study population. A description of the population under-
studied is displayed in Table 1.
In over 70% of patients, less than three adenomas were
detected. Most were located distally to the splenic flexure
(82%) and were larger or equal to 10 mm in size (64%).
Histologically, high-grade dysplasia was described in 33% of
index adenomatous polyps.
High-risk patients for adenoma recurrence (adenoma with
villous histology or high-grade dysplasia or ≥10 mm in size, or
≥ 3 adenomas) represented 72% of cases’ population. The
median follow-up time was 76 months (22–201) and meta-
chronous lesions were identified in 46% of patients with
personal history of adenomas. No differences were observed
between these patients and the ones without adenoma
recurrence during the follow-up period.
Risk estimates for the development of colorectal ade-
noma. A total of 43 SNPs were included in the risk estimate
analysis. The description of selected SNPs and distribution of
genotypes are displayed in Supplementary Tables 1 and 2,
respectively. Twenty-three polymorphisms were associated
with the development of colorectal adenomas, as observed in
Table 2. To address for possible bias in these positive findings,
the FPRP was also analyzed, with 10 polymorphisms
Figure 1 Methods of sampling for controls and cases.
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retaining their association with colorectal adenoma onset.
Different prior probabilities within the 0.01–0.1 range were
assumed, with the highest cut-off of 0.1 assigned to the
rs689466 and rs2555639 polymorphisms in COX-2 and
HPGD genes, respectively, considering the predicted biologi-
cal impact and previous epidemiological evidence in color-
ectal carcinogenesis.15,17,19,20 FPRP values below 0.5
suggest that the observed associations could represent
false-positive reports.
The most noteworthy genetic variants include the rs689466
in COX-2 (OR=3.23; 95% CI: 1.52–6.86, P=0.002),
rs2555639 and rs12500316 in HPGD (OR= 2.48; 95% CI:
1.36–4.53, P=0.003 and OR=0.49; 95% CI: 0.31–0.78,
P=0.002, respectively), rs6439448 in SLCO2A1 (OR= 0.38;
95%CI: 0.22–0.65,Po0.001) and rs9524821, rs1751051 and
rs1678405 in ABCC4 genes (OR= 2.38; 95% CI: 1.39–4.09,
P=0.002; OR= 2.75; 95% CI: 1.58–4.80, Po0.001 and
OR=0.41; 95% CI: 0.27–0.63, Po0.001, correspondingly),
with an individual associated OR≥ 2 for the development of
colorectal adenomatous polyps, or corresponding OR≤ 0.5.
The involvement of genetic variants in PGE2 pathway genes
on the recurrence of adenomaswas negligible upon the FPRP
analysis, potentially indicating false-positive associations
(FPRP40.5; see Supplementary Table 3) or low power,
considering we hado200 patients.
Haplotype analysis for the development of colorectal
adenomas. The frequencies of derived haplotypes from
HPGD, SLCO2A1, and ABCC4 genes are presented in
Table 3. In ABCC4 gene, the most frequent haplotype, the
GTT, was present in 27% of controls and used as the
reference one. The block carrying the rs9524821A and
rs1751051A alleles boosted even further the susceptibility
Table 1 Description of population
Controls (n=480) Adenomas (n= 195) P value Recurrence P value
No Yes
Demographics
Age (years)
Mean (s.d.) 58 (4.90) 61 (6.78) – 61 (6.64) 61 (6.74) –
Median (min–max) 58 (50–69) 61 (50–75) o0.001 61 (50–75) 60 (50–75) 0.698
Sex, n (%)
Male 314 (65.4) 110 (57.3) – 54 (49.5) 55 (50.5) –
Female 166 (34.6) 82 (42.7) 0.159 48 (60.0) 32 (40.0) 0.154
Lifestyle behaviors
Smoking status, n (%)
Never-smokers 219 (60.3) 86 (71.7) – 47 (54.7) 39 (45.3) –
Ever-smokers 144 (39.7) 34 (28.3) 0.075 16 (47.1) 18 (52.9) 0.453
High-risk patientsa
No – 53 (27.9) – 27 (54.0) 23 (46.0) –
Yes – 137 (72.1) – 74 (53.6) 64 (46.4) 0.963
Time of follow-up (mo)
Mean (s.d.) – 80.1 (39.5) – – – –
Median (min–max) – 76 (22–201) – – – –
Polyps characteristics
Number of adenomas
Mean (s.d.) – 2.15 (1.69) – 1.98 (1.51) 2.38 (1.87) –
Median (min–max) – 1 (1–10) – 1 (1–9) 2 (1–10) 0.119
o3 – 133 (70.7) – 74 (55.6) 59 (44.4) –
≥3 – 55 (29.3) – 27 (49.1) 28 (50.9) 0.413
Tumor location, n (%)
Distal – 155 (82.0) – 87 (56.1) 68 (43.9) –
Proximal – 34 (18.0) – 15 (44.1) 19 (55.9) 0.203
Size, n (%)
o10 – 67 (35.6) – 37 (55.2) 30 (44.8) –
≥10 – 121 (64.4) – 65 (53.7) 56 (46.3) 0.843
Morphology, n (%)
Pedunculated – 76 (46.1) – 42 (55.3) 34 (44.7) –
Sessile – 89 (53.9) – 42 (47.2) 47 (52.8) 0.301
Histological Grade, n (%)
Low-grade dysplasia – 127 (67.2) – 67 (52.8) 60 (47.2) –
High-grade dysplasia – 62 (32.8) – 35 (56.5) 27 (43.5) 0.632
Histological type, n (%)
Tubular – 30 (46.1) – 16 (53.3) 14 (46.7) –
Tubulovillous – 20 (30.8) – 14 (70.0) 6 (30.0) –
Villous – 15 (23.1) – 9 (60.0) 6 (40.0) 0.446
Metachronous adenomas
No – 102 (54) – – – –
Yes – 87 (46) – – – –
max, maximum; min, minimum; mo, months.
arisk stratification for adenoma recurrence based on the endoscopic findings at baseline colonoscopy. Low-risk patients: 1–2 tubular adenomaso10 mm in size with
low -grade dysplasia; High-risk patients: patients with adenomas with villous histology or high-grade dysplasia or ≥ 10 mm in size, or ≥ 3 adenomas.
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for colorectal precancerous lesion reported in the individual
analysis (OR=3.90; 95% CI: 2.28–6.65, Po0.001).
Gene–gene interaction analysis in the development of
colorectal adenoma. To address possible interactions
between the noteworthy SNPs from the main analysis, an
exhaustive multifactor dimensionality reduction approach was
employed and Table 4 summarizes the best interactive
models obtained. The best four-locus model achieved the
highest testing accuracy of 78% for predicting the develop-
ment of colorectal adenomas, with a cross-validation con-
sistency of 8/10. This interaction model included the
rs1346271, rs1863642, and rs12500316 polymorphisms in
HPGD gene and rs1678405 in ABCC4 gene and was
associated with a 13-fold increased risk for the development
of adenomas (95% CI: 3.84–46.3, Po0.0001).
Influence on the time to adenoma recurrence and crude
risk. We next inquired if polymorphisms in these key genes
in PGE2 pathway could influence not only the time but also
the crude risk for adenomas recurrence at 36, 60, and
120 months, following the recommendations for post-
polypectomy colonoscopy surveillance (Table 5).21 Although
no difference was observed on the time to adenoma
Table 2 Risk estimates for the involvement of COX-2/HPGD/SLCO2A1/ABCC4 polymorphisms in colorectal adenoma development (only statistical significant
data is presented)
SNP Model of inheritance aOR 95% CI P value Pbootstrap FPRP prior probability
0.01 0.05 0.1
COX-2
rs689466 Recessive (AA/AGvsGG) 3.23 1.52–6.86 0.002 0.001 0.908 0.654 0.472a
HPGD
rs2555639 Recessive (TT/TCvsCC) 2.48 1.36–4.53 0.003 0.002 0.859 0.538 0.356a
rs2612656 Dominant (AAvsAG/GG) 0.47 0.23–0.94 0.033 0.035 0.953 0.794 0.646
Recessive (AA/AGvsGG) 3.20 1.22–8.41 0.018 0.009 0.967 0.848 0.726
rs8752 Recessive (AA/AGvsGG) 1.94 1.09–3.44 0.023 0.036 0.924 0.701 0.526
rs1346271 Dominant (GGvsGC/CC) 0.55 0.35–0.85 0.008 0.013 0.785 0.411 0.249
rs1863642 Dominant (GGvsGT/TT) 0.55 0.36–0.85 0.007 0.008 0.785 0.411 0.249
rs12500316 Dominant (CCvsCT/TT) 0.49 0.31–0.78 0.002 0.002 0.729 0.340 0.196
SLCO2A1
rs4241362 Recessive (TT/TCvsCC) 3.90 1.80–8.43 0.001 0.001 0.876 0.575 0.391
rs6439448 Dominant (CCvsCA/AA) 0.38 0.22–0.65 o0.001 0.002 0.670 0.280 0.156
rs9821091 Dominant (GGvsGA/AA) 0.62 0.40–0.96 0.033 0.044 0.895 0.621 0.437
Recessive (GG/GAvsAA) 1.77 1.02–3.06 0.041 0.048 0.936 0.738 0.571
rs4241365 Recessive (TT/TCvsCC) 2.60 1.30–5.22 0.007 0.006 0.921 0.692 0.516
SLCO2A1
rs7625035 Recessive (AA/AGvsGG) 2.68 1.71–6.11 0.020 0.026 0.957 0.812 0.672
rs1131598 Dominant (AAvsAG/GG) 0.58 0.41–0.84 0.018 0.052 0.629 0.245 0.133
rs10935090 Recessive (CC/CTvsTT) 5.18 1.33–20.17 0.018 0.002 0.979 0.901 0.812
ABCC4
rs9524821 Recessive (GG/GAvsAA) 2.38 1.39–4.09 0.002 0.003 0.780 0.405 0.244
rs869951 Dominant (GGvsGC/CC) 0.60 0.39–0.92 0.018 0.019 0.858 0.537 0.354
rs1751051 Recessive (TT/TAvsAA) 2.75 1.58–4.80 o0.001 0.001 0.691 0.300 0.169
rs2892713 Recessive (CC/CTvsTT) 2.50 1.12–5.58 0.025 0.006 0.959 0.819 0.682
rs4612933 Recessive (CC/CTvsTT) 3.03 1.35–6.79 0.007 0.005 0.941 0.754 0.593
rs4148476 Recessive (TT/TGvsGG) 3.22 1.41–7.36 0.005 0.005 0.940 0.751 0.588
rs1678405 Dominant (TTvsTC/CC) 0.41 0.27–0.63 o0.001 0.001 0.261 0.064 0.031
Recessive (TT/TCvsCC) 0.15 0.04–0.63 0.010 0.010 0.979 0.897 0.805
rs1751031 Recessive (AA/AGvsGG) 2.99 1.11–8.00 0.030 0.016 0.971 0.867 0.756
rs7993878 Recessive (GG/GAvsAA) 3.14 1.09–9.01 0.033 0.024 0.975 0.882 0.780
aOR, Odds ratio, logistic regression (Forward:conditional model) including age, sex and smoking habits as covariates; CI, confidence interval; FPRP, false-positive
report probability; SNP, single nucleotide polymorphism.
aA prior probability of 0.1 was assumed for the rs689466 and rs2555639 considering the available epidemiologic and functional data;15,17,19,20 For all other
polymorphisms without previous evidences, a lower prior probability of 0.05 was considered. Only statistical significant associations are presented (Po0.05). Bold for
FPRPo0.5, i.e., the statistical associations are less likely to represent false-positive findings.
Table 3 Haplotype frequencies between patients and controls and risk
estimates for their involvement in adenoma development
Gene/
haplotype
Cases (%) Controls (%) aOR 95% CI P value
HPGDa
C-G-G-T 35.0 28.0 1 Reference –
C-G-G-C 18.6 10.9 1.04 0.64–1.70 0.87
C-C-G-T 15.3 9.1 1.11 0.68–1.82 0.67
T-G-G-T 1.1 12.6 0.05 0.01–0.15 o0.001
C-C-T-T 0 10.4 – – –
C-C-T-C 0.8 8.8 0.06 0.01–0.33 0.001
SLCO2A1b
A-C 71.6 60.8 1 Reference –
G-C 17.2 20.8 0.68 0.49–0.95 0.024
A-A 8.4 15.4 0.50 0.33–0.76 0.001
ABCC4c
G-T-T 19.8 26.9 1 Reference –
A-T-T 26.8 19.7 1.85 1.19–2.86 0.006
G-C-T 15.3 17.0 1.18 0.71–1.98 0.52
G-T-A 14.3 14.4 1.51 0.89–2.56 0.13
A-T-A 17.3 3.9 3.90 2.28–6.65 o0.001
G-C-A 5.7 6.1 0.99 0.46–2.12 0.98
aOR, Odds ratio adjusted for age, sex and smoking habits; CI, confidence
interval; OR, Odds ratio.
aSNPs order: rs12500316-rs1346271-rsrs1863642-rs2555639.
bSNPs order: rs1131598-rs6439448.
cSNPs order: rs9524821-rs1678405-rs1751051. Bold for Po0.001.
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recurrence (112 vs. 105 months, P=0.788) or recurrence
rate (46%, P= 0.996) between the high and low-risk patients,
14% of all adenomatous polyps recurred at 36 in the high-risk
group in contrast to the 2% reported in low-risk patients. In
addition, nearly 95% (18/19) of metachronous advanced
adenomas were described in the high-risk group, with 28 and
67% being diagnosed at 36 and 60 months (data not shown).
The rs9524821AA genotype not only was associated with a
nearly threefold increased susceptibility in the cox regression
analysis (95% CI:1.07–8.03, P= 0.036), but half of patients
carrying this genotype had adenoma recurrence at 60months,
considerably higher than the 21% noticed in low-risk patients.
Similarly, patients’ carriers of rs2274403AA genotype had a
lower interval until recurrence (85 (29–140) vs. 122 (109–135),
P=0.011) with 44% of metachronous tumors developing by
36 months (vs. 23% for AG/GG).
DISCUSSION
CRC remains a major clinical and public health challenge that
could be averted by applying the current knowledge about
CRC prevention and improving the adherence to established
screening guidelines.4,5
The search for susceptibility biomarkers in colorectal carcino-
genesis might reveal an important tool to select unscreened
individuals to CRC screening or even to complementary
chemopreventive strategieswith nonsteroidal anti-inflammatory
drugs (NSAIDs) by allowing the identification of individuals at
higher risk for the development of colorectal tumors.
The efflux-dominated flow of PG during carcinogenesis as a
reflection of an increased expression of COX-2 and MRP4,
and down regulation of 15-PGDH and PGT lead to an
accumulation of PGE2 in the extracellular milieu culminating
Table 4 MDR analysis for the colorectal adenoma risk prediction
Best model CV accuracy CV consistency aOR 95% CI P value
rs1346271, rs12500316 0.6964 9/10 5.41 1.88–15.5 0.001
rs1346271, rs1863642, rs12500316 0.7006 6/10 5.51 1.90–15.9 0.001
rs1346271, rs1863642, rs12500316, rs1678405 0.7816 8/10 13.3 3.84–46.3 o0.001
aOR, Odds ratio adjusted for age, sex and smoking habits; CI, confidence interval; CV, cross-validation; MDR, multifactor dimensionality reduction.
Table 5 Influence of genetic variations in COX-2/HPGD/SLCO2A1/ABCC4 on the time to recurrence of colorectal adenomas and crude risk of recurrence at 36, 60,
and 120 months of follow-up
Recurrence (%) aOR (95% CI) aHR (95% CI) Time to recurrencea
(min–max)
Crude risk for
recurrence (%)
36 mo 60 mo 120 mo
Low-risk individuals
Global – 46 – – 112 (100–124) 2 21 86
SLCO2A1
rs9820625 AA/AC 32 10.71 (1.17–
98.24)
3.33 (1.22–9.10) 115 (100–130) 3 16 70
CC 80 – – 85 (62–108) 0 29 100
ABCC4
rs9524821 GG/GA 41 – 2.93 (1.07–8.03)a 122 (97–147) 4 16 78
AA 43 – – 107 (57–157) 0 48 100
rs1678396 TT 50 – 0.20 (0.07–0.60) 94 (90–98) 0 18 100
TC/CC 39 – – 122 (95–149) 3 18 80
rs2274403 AA 50 – 0.26 (0.08–0.83) 85 (29–140) 0 44 69
AG/GG 39 – – 122 (109–135) 3 23 83
rs3742106 AA 21 5.36 (1.25–23.04) 5.78 (1.61–20.8) 135 (77–193) 0 8 72
AC/CC 59 105 (84–126) 3 27 92
rs6492763 TT 73 0.18 (0.04–0.74) 0.26 (0.07–0.91) 93 (55–130) 6 38 100
TC/CC 15 – – 176 (− ) 0 7 66
rs869951 GG/GC 35 – – 114 (105–123) 3 17 89
CC 75 – – 66 (48–84) 0 50 100
High-risk individuals
Global 46 – – 105 (87–123) 14 27 82
SLCO2A1
rs1131598 AA/AG 44 – 3.23 (1.49–7.02) 105 (86–124) 13 23 81
GG 73 – – 67 (59–74) 19 59 100
rs7616492 GG 57 – – 94 (78–110) 14 40 94
GA/AA 39 – – 121 (98–143) 13 20 74
rs7340717 GG/GT 44 – – 115 (88–142) 12 26 81
TT 57 – – 94 (43–145) 26 47 93
ABCC4
rs1678405 TT 39 2.09a (1.04–4.23) 1.75a (1.05–2.91) 109 (89–129) 7 22 77
TC/CC 57 – – 90 (76–104) 23 35 88
aOR, Odds ratio: logistic regression with center as covariate; aHazard Ratio, cox regression including center as covariate; CI, confidence interval; max, maximum;min,
minimum; mo, month.
aP40.05 upon the bootstrap analysis based in 1,000 samples.
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in the activation of a plethora of pathways that stimulate tumor
development.14
In the present study, we addressed the role of 43 tagSNPS in
four candidate genes (COX-2/HPGD/SLCO2A1/ABCC4) of
COX-2/PGE2 pathway on the development and recurrence of
colorectal adenomatous polyps in a northern Portuguese
population. Recently, using the same tagSNPs approach and
targeting the same pathwaywe also identified the rs689466A4G
polymorphism in COX-2, the rs1346271G4C in HPGD, the
rs6439448C4A inSLCO2A1 and the rs1751051T4A inABCC4
genes polymorphisms as susceptibility biomarkers for CRC,
supporting the associations reported here and the role theymight
portray in colorectal carcinogenesis.15
The homozygous GG genotype for the rs689466 SNP, also
known as -1195A4G COX-2 polymorphism, associated
presently with a threefold higher predisposition, was previously
relatedwith a higher risk for duodenal adenomatosis in patients
with familial adenomatous polyposis (FAP).22 Although repre-
senting a hereditary syndrome, deregulation of COX-2
expression was observed in normal and duodenal adenomas
of FAP patients.23 Furthermore, our group, in an earlier study
observed a higher transcriptional activity in HCT116 and
HCA-7 CRC cell lines transfected with COX-2 promoters’
encompassing the rs689466G allele.19 Thereby, providing a
biological plausibility for the epidemiological observations.
Thompson et al.20 first associated the rs2555639T4C SNP
located at 17.74 kb upstream the 5′UTR of HPGD gene with a
40% increased risk for CRC in TT homozygous carriers.
Surprisingly, in our population, this SNP not only appears to be
more relevant in early stages of colorectal carcinogenesis, but the
opposing rs2555639CC genotype was linked to colorectal
adenomas onset. This conflicting data might reflect population
stratification involving different genetic ancestry, considering that
the initial study involved participants from the Kentucky Surveil-
lance, Epidemiology and End Results (SEER) registry most likely
with northern or western European ancestry (English, German
and Irish ancestry). Furthermore, the rs12500316C4T tagSNP
in HPGD gene also displayed a protective role in colorectal
adenoma onset in a previous study reported by Edwards et al.24
The PGT and MRP4 specific PG membrane transporters
are encoded by highly polymorphic genes. Still, the study of
genetic variants in SLCO2A1 and ABCC4 genes on the
etiology of malignant diseases has been rather neglected.15,25
In our population, A allele carriers of the rs6439448 tagSNP in
SLCO2A1 presented a 60% protection for colonic adenoma
development. Biologically, the rs6439448 SNP tags two other
polymorphisms with predicted impact on PGTexpression: the
rs2370512T4A in the 3′UTR could affect the binding of
microRNAs and stability of messenger RNA and the non-
synonymous rs34550074G4A SNP at codon 396 codes for
two different amino acids (Ala396Thr) with potential repercus-
sion on protein structure and function (SNPinfo software).
Remarkably, homozygous mutations in HPGD and more
recently inSLCO2A1 genewere identified as causative agents
for the development of primary hypertrophic osteoarthropathy
(PHO).26,27 Similarly to neoplastic tumor genesis, increased
levels of PGE2 play a role in the pathogenesis of PHO, thus
reinforcing the impact that genetic variability in these genes
might portray in disease development by disrupting the normal
15-PGDH and PGT levels or activity.27
More interesting, individuals carrying the haplotype contain-
ing the A allele for the rs9524821 and rs1751051 SNPs in
ABCC4 gene had a nearly fourfold increased susceptibility.
The in silico analysis did not provide any biological clue for the
involvement of these polymorphisms in MRP4 expression or
function.
The common disease-common variant (CD-CV) hypothesis
predicts that complex polygenic diseases develop from the
additive or multiplicative effect of low penetrance genes.28
Here, a 13-fold increased predisposition was noticed in the
multi-locus analysis, supporting the role that common variants
portray in colorectal carcinogenesis.
The current post-polypectomy guidelines recommend
endoscopic surveillance based on risk stratification upon the
endoscopic findings at baseline colonoscopy.21 In the present
study, we observed that polymorphisms in the COX-2/PGE2
pathway, particularly on the ABCC4 gene, appear to influence
not only the hazard ratio for the development of metachronous
adenomas, but perhaps more importantly, the probability of
recurrence considering the surveillance intervals currently
recommended. As an example, the individuals carrying the
rs9524821AA genotype in the low-risk group presented a
nearly threefold increased hazard ratio for adenoma recur-
rence and nearly half of them developed metachronous
lesions by 60 months (vs. 16%, for G allele carriers).
Further research with larger and independent populations
should be warranted as the data here presented, although
suggesting the involvement of genetic variants in PGE2
pathway in the development and recurrence of adenomas,
derives from an underpowered proof-of-concept study.
Furthermore, and following a retrospective study design we
cannot rule out recall bias that could decrease the availability
and accuracy of collected data, compromising our ability to
estimate possible gene-environment interactions or selection
bias. First, our control population was represented by
unscreened individuals. Although if this was the case, stronger
associations would be expected; and second, an enrichment
towards the diagnosis of advanced adenomas was observed
(72%), albeit this study included all patients with personal
history of adenomas that gathered the inclusion criteria. This
might potentially be explained since caseswere recruited from
tertiary care hospitals, including a cancer specialized center.
In fact, patients from the cancer institute had a higher
frequency of high-grade dysplasia (45 vs. 19%) and sessile
adenomas (65 vs. 40%). When studying the recurrence of
adenomatous polyps the recruitment center was included as a
covariate in the logistic regression analysis. Moreover, no
difference in the distribution of genotypes was observed
considering histopathological features.
In the absence of a replication study, the bootstrap resampling
or cross-validation consistency methods were used to test the
robustness, performance and internal validity of our analyses.
Functional studies are also needed to evaluate the
repercussion of the aforementioned SNPs on protein expres-
sion/function to allow a deeper understanding of their real
contribution on cancer development.
In this study, we observed the involvement of several
polymorphisms in COX-2/HPGD/SLCO2A1/ABCC4 genes in
colorectal adenoma development and recurrence. If corrobo-
rated by future research, the definition of genetic profiles might
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Pereira et al.
7
Clinical and Translational Gastroenterology
have the potential to represent a tool to optimize current
screening and surveillance guidelines.
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WHAT IS CURRENT KNOWLEDGE
• Deregulation of COX-2/PGE2 pathway is observed in
colorectal cancer and is involved in key steps of tumor
development.
• The genetic background plays a role in cancer development.
WHAT IS NEW HERE
• Genetic variability in COX-2/HPGD/SLCO2A1/ABCC4
genes influences the risk for the development and
recurrence of colorectal adenomas.
• Polymorphisms in SLCO2A1 and ABCC4 alter the interval
time to adenoma recurrence and crude risk at 36, 60, and
120 months.
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